These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 28224267

  • 1. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
    Sett A, Borthakur BB, Bora U.
    Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
    [Abstract] [Full Text] [Related]

  • 2. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.
    Dastjerdi K, Tabar GH, Dehghani H, Haghparast A.
    Biotechnol Appl Biochem; 2011 Aug; 58(4):226-30. PubMed ID: 21838796
    [Abstract] [Full Text] [Related]

  • 3. Selection of a novel DNA thioaptamer against HER2 structure.
    Hu Y, Duan J, Cao B, Zhang L, Lu X, Wang F, Yao F, Zhu Z, Yuan W, Wang C, Yang XD.
    Clin Transl Oncol; 2015 Aug; 17(8):647-56. PubMed ID: 26022131
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
    Liu Z, Duan JH, Song YM, Ma J, Wang FD, Lu X, Yang XD.
    J Transl Med; 2012 Jul 20; 10():148. PubMed ID: 22817844
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Reix N, Malina C, Chenard MP, Bellocq JP, Delpous S, Molière S, Sevrin A, Neuberger K, Tomasetto C, Mathelin C.
    Breast Cancer Res Treat; 2016 Nov 20; 160(2):249-259. PubMed ID: 27709352
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selection of an aptamer against mouse GP2 by SELEX.
    Hanazato M, Nakato G, Nishikawa F, Hase K, Nishikawa S, Ohno H.
    Cell Struct Funct; 2014 Nov 20; 39(1):23-9. PubMed ID: 24334484
    [Abstract] [Full Text] [Related]

  • 12. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.
    Mahlknecht G, Sela M, Yarden Y.
    Methods Mol Biol; 2015 Nov 20; 1317():3-15. PubMed ID: 26072398
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Revealing the molecular interactions of aptamers that specifically bind to the extracellular domain of HER2 cancer biomarker protein: An in silico assessment.
    Niazi S, Purohit M, Sonawani A, Niazi JH.
    J Mol Graph Model; 2018 Aug 20; 83():112-121. PubMed ID: 29902673
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity.
    Wang DL, Song YL, Zhu Z, Li XL, Zou Y, Yang HT, Wang JJ, Yao PS, Pan RJ, Yang CJ, Kang DZ.
    Biochem Biophys Res Commun; 2014 Oct 31; 453(4):681-5. PubMed ID: 25242523
    [Abstract] [Full Text] [Related]

  • 19. Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Okarvi SM, Aljammaz I.
    Anticancer Res; 2018 May 31; 38(5):2823-2830. PubMed ID: 29715105
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.